[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100425599":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":37,"responsibleParty":111,"collaborators":20,"id":115,"slug":20,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":116,"sex":122,"minAge":123,"maxAge":20,"enrollmentInfo":124,"targetDuration":20,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":135,"overallStatus":40,"whyStopped":20,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},{"fullName":5,"class":6},"Swedish Lung Cancer Study Group","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Proton radiotherapy","EXPERIMENTAL","Proton radiotherapy with RBE doses:\n\n* Patients with radical surgery and unfavourable histology (B2, B3, C) and\u002For Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).\n* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)\n* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)",[13],"Radiation: Proton radiation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Proton radiation","* Patients with radical surgery and unfavourable histology (B2, B3, C) and\u002For Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).\n* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)\n* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Hillevi Rylander, MD","Head of Skandion Clinic","STUDY_DIRECTOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Jan Nyman, Ass.prof.","CONTACT","+46313421000","27927","jan.nyman@oncology.gu.se",{"name":34,"role":29,"phone":35,"phoneExt":20,"email":36},"Andreas Hallqvist, MD, PhD","+46739845114","andreas.hallqvist@vgregion.se",[38,64,84],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Department of Oncology, Norrlands Universitetssjukhus","RECRUITING","Umeå","Norrland","901 85","Sweden",{"type":46,"coordinates":47},"Point",[48,49],20.25972,63.82842,{"lat":49,"lon":48},[52,56,59,61],{"name":53,"role":29,"phone":54,"phoneExt":20,"email":55},"Mikael Johansson, MD PhD","0046703711414","mikael.johansson@onkologi.umu.se",{"name":57,"role":29,"phone":20,"phoneExt":20,"email":58},"Per Bergström, MD PhD","per.bergstrom@vll.se",{"name":53,"role":60,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"name":62,"role":63,"phone":20,"phoneExt":20,"email":20},"Per Bergström, MD","SUB_INVESTIGATOR",{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":44,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Department of Oncology, Karolinska University Hospital","NOT_YET_RECRUITING","Stockholm","Stockholm County","171 76",{"type":46,"coordinates":71},[72,73],18.06871,59.32938,{"lat":73,"lon":72},[76,79,82,83],{"name":77,"role":29,"phone":20,"phoneExt":20,"email":78},"Signe Friesland, MD PhD","signe.friesland@sll.se",{"name":80,"role":29,"phone":20,"phoneExt":20,"email":81},"Michael Gubanski, MD PhD","michael.gubanski@sll.se",{"name":77,"role":60,"phone":20,"phoneExt":20,"email":20},{"name":80,"role":63,"phone":20,"phoneExt":20,"email":20},{"facility":85,"status":40,"city":86,"state":87,"zip":88,"country":44,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Department of Oncology, Sahlgrenska University Hospital","Gothenburg","Västra Götaland County","413 45",{"type":46,"coordinates":90},[91,92],11.96679,57.70716,{"lat":92,"lon":91},[95,98,99,101,103,104,106,108,110],{"name":96,"role":29,"phone":97,"phoneExt":20,"email":32},"Jan Nyman, Ass prof","0046313427927",{"name":34,"role":29,"phone":35,"phoneExt":20,"email":36},{"name":100,"role":63,"phone":20,"phoneExt":20,"email":20},"Andreas Hallqvist, MD PhD",{"name":102,"role":63,"phone":20,"phoneExt":20,"email":20},"Annica Ravn-Fischer, MD phD",{"name":23,"role":63,"phone":20,"phoneExt":20,"email":20},{"name":105,"role":63,"phone":20,"phoneExt":20,"email":20},"Anna Bäck, PhD",{"name":107,"role":63,"phone":20,"phoneExt":20,"email":20},"Erik Lundin, MD",{"name":109,"role":63,"phone":20,"phoneExt":20,"email":20},"Jens Engleson, MD",{"name":96,"role":60,"phone":20,"phoneExt":20,"email":20},{"type":112,"investigatorFullName":113,"investigatorTitle":114,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Ass. Prof. Jan Nyman","Head of Swedish Lung Cancer Study Group, Ass. Prof.","100425599",false,"NCT04822077","Study on Proton Radiotherapy of Thymic Malignancies","PROTHYM - Phase II Non-randomized Study on Proton Radiotherapy Of Thymic Malignancies","PROTHYM","Inclusion Criteria:\n\n* Histological or cytological diagnosis of thymoma or thymic carcinoma.\n* With radical surgery: stage III and IVa and selected stage II with type B2, B3 and thymic carcinoma according to local routine. With non-radical surgery (R1 or R2) or inoperable patient\u002F patient refusing surgery: stage I - IVa, any histology\n* PS WHO 0 - 2.\n* FEV1 \\> 1L or \\>40 % of predicted and CO diffusion capacity \\> 40% of predicted (postoperative measures)\n* Age \\>18 years, no upper age limit.\n* Written informed consent from patients.\n\nExclusion Criteria:\n\n* Masaoka-Koga stage IVb (distant metastases).\n* Pregnancy.\n* Serious concomitant systemic disorder incompatible with the study.\n* Tumour motion \\> 0.5 cm on two repeated 4DCT","ALL","18 Years",{"count":125,"type":126},40,"ESTIMATED","INTERVENTIONAL",[129],"NA","This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative setting or in inoperable patients with localized disease.\n\nPatients not willing or for any reason unsuitable to undergo proton treatment will be asked to participate in a follow-up assessment after the regular photon treatment in the same manner as the included patients.\n\nPrimary endpoints are:Toxicity (e.g. cardiac and pulmonary toxicity) and Local control at 5 year Secondary endpoints: PFS, Overall survival, Quality of life, measured by EORTC QLQ 30 + LC 13 and relapse pattern",[132,133,134],"Cardiotoxicity","Pulmonary Toxicity","Thymus Neoplasms",[136,137,9],"Thymoma","Thymic carcinoma","2021-03-25",{"date":140,"type":141},"2021-03-30","ACTUAL",{"date":143,"type":141},"2018-04-18",{"date":145,"type":126},"2029-04-01",{"name":113,"class":6},3]